AI-native biotechnology company BaiAo Geometry has successfully secured several hundred million yuan in strategic financing, with investments led by the Shanghai Biomedical Innovation Transformation Fund, Guoke Investment, Dacheng Wisdom, and Xinglian Capital, alongside follow-on investments from GaoRong Capital and the Index AI Industry Innovation Fund. The funds will primarily support the ongoing development of their life sciences micro-world model, GeoFlow, and the advancement of their proprietary drug pipeline.
Artificial intelligence is rapidly evolving along two main trajectories: digital AI, represented by large language and multimodal models, and physical AI, exemplified by autonomous vehicles and humanoid robots. Life AI is emerging as a promising frontier, a sentiment echoed by leading global investors and scientists. BaiAo Geometry's GeoFlow model, launched in 2024, aims to understand and design molecular interactions at an atomic level, enabling the creation of novel molecules that have never existed in nature.
The company has iterated GeoFlow multiple times, achieving significant advancements in protein structure prediction and de novo design capabilities. By applying Test-Time Scaling technology, BaiAo Geometry enhances the success rate of protein designs without the need for extensive retraining. This innovation allows for the rapid generation and optimization of high-affinity binding molecules, significantly reducing the time and cost associated with traditional drug discovery processes.
BaiAo Geometry has established over 20 business development collaborations with domestic and international pharmaceutical companies, focusing on high-specificity antibody design and vaccine development. The company is currently working on the next iteration of GeoFlow, which aims to expand modeling from individual molecules to entire molecular systems, further revolutionizing drug development in the biotechnology sector.
Leave a comment